Compare UTMD & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UTMD | KRRO |
|---|---|---|
| Founded | 1978 | 2014 |
| Country | United States | United States |
| Employees | N/A | 57 |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 235.3M | 204.1M |
| IPO Year | 1994 | 2019 |
| Metric | UTMD | KRRO |
|---|---|---|
| Price | $67.88 | $13.98 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $20.20 |
| AVG Volume (30 Days) | 31.5K | ★ 186.7K |
| Earning Date | 10-22-2026 | 11-11-2026 |
| Dividend Yield | ★ 1.80% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.66 | N/A |
| Revenue | ★ $38,520,000.00 | $6,392,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $56.67 |
| P/E Ratio | $41.77 | ★ N/A |
| Revenue Growth | N/A | ★ 181.46 |
| 52 Week Low | $53.66 | $5.20 |
| 52 Week High | $76.89 | $42.70 |
| Indicator | UTMD | KRRO |
|---|---|---|
| Relative Strength Index (RSI) | 22.57 | 70.98 |
| Support Level | $66.40 | $9.43 |
| Resistance Level | $72.81 | $14.69 |
| Average True Range (ATR) | 1.28 | 1.05 |
| MACD | -0.83 | 0.62 |
| Stochastic Oscillator | 2.32 | 97.51 |
Utah Medical Products Inc is involved in the business of developing, manufacturing, and distributing medical devices that are mainly proprietary, disposable, and for hospital use. The firm produces its products for Blood pressure monitoring, Blood collection, Electrosurgery, Gynecology, Neonatal critical care, perinatology, and Urology. The company's product portfolio includes Electrosurgical pens, Tenacula, Endoscopic bulb irrigators, and Blood bag spikes. Its products are used mainly in critical care areas, labor and delivery departments of hospitals, and outpatient clinics and physicians' offices.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.